HER家族在乳腺癌靶向治疗中的研究进展

Progress of HER Family Targeted Drugs in Breast Cancer Treatment

分子靶向治疗由于具有特异性强、效果显著、不良反应小的特点,现已应用于乳腺癌治疗。近年来研发发现作用于人类表皮生长因子受体(HER)家族的靶向药物和多靶点药物,且药物间可以联合使用。针对乳腺癌患者采取分子靶向治疗临床效果确切,其可以明显提高治疗有效率,降低复发率,并且毒性小,值得临床推广应用,对于具备分子靶向治疗条件的乳腺癌患者应该作为首选治疗方案。

Because of its specificity, significant effect and low side effect, molecular targeted therapy has been applied in the treatment of breastcancer. Recently, various molecular targeted drugs have been exploited, such as targeted HER family, multi-targeted therapeutic drugs, and drugscombination. Molecular targeted therapy in patients with breast cancer has exact curative effect,which can significantly improve effective rate andreduce the recurrence rate and the toxicity. Thus, it is worthy of clinical promotion and application.Molecular targeted therapy should be the preferredtherapeutic schedule for patients with breast cancer.